Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nirmatrelvir Plus Ritonavir: First Approval
Yvette N. Lamb
Drugs (2022) Vol. 82, Iss. 5, pp. 585-591
Open Access | Times Cited: 240

Showing 1-25 of 240 citing articles:

Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 113
SARS-CoV-2 3CL pro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
Emmanuel Heilmann, Francesco Costacurta, Seyed Arad Moghadasi, et al.
Science Translational Medicine (2022) Vol. 15, Iss. 678
Open Access | Times Cited: 105
Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure–Activity Relationship Insights and Evolution Perspectives
Gabriele La Monica, Alessia Bono, Antonino Lauria, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 12500-12534
Open Access | Times Cited: 100
Recent Advances in Covalent Drug Discovery
D. M. Schaefer, Xinlai Cheng
Pharmaceuticals (2023) Vol. 16, Iss. 5, pp. 663-663
Open Access | Times Cited: 42
Cardiovascular disease as part of Long COVID: a systematic review
Vasiliki Tsampasian, Maria Bäck, Marco Bernardi, et al.
European Journal of Preventive Cardiology (2024)
Open Access | Times Cited: 15
Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase
Zhonglei Wang, Liyan Yang, Xian-qing Song
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection
Zhifen Cui, Cong Zeng, Furong Huang, et al.
Nature Chemical Biology (2022) Vol. 18, Iss. 10, pp. 1056-1064
Open Access | Times Cited: 46
Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience
Giusy Tiseo, Chiara Barbieri, Valentina Galfo, et al.
Infectious Diseases and Therapy (2022) Vol. 12, Iss. 1, pp. 257-271
Open Access | Times Cited: 45
SARS‐CoV‐2 Papain‐Like Protease: Structure, Function and Inhibition
Sven Ullrich, Christoph Nitsche
ChemBioChem (2022) Vol. 23, Iss. 19
Open Access | Times Cited: 43
Nitriles: an attractive approach to the development of covalent inhibitors
Vinícius Bonatto, Rafael F. Lameiro, Fernanda dos Reis Rocho, et al.
RSC Medicinal Chemistry (2022) Vol. 14, Iss. 2, pp. 201-217
Open Access | Times Cited: 40
Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
Meng-Meng Lin, Xudong Zeng, Yinkai Duan, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 33
Antiviral PROTACs: Opportunity borne with challenge
Jinsen Liang, Yihe Wu, Ke Lan, et al.
Cell Insight (2023) Vol. 2, Iss. 3, pp. 100092-100092
Open Access | Times Cited: 32
Green and efficient one-pot three-component synthesis of novel drug-like furo[2,3-d]pyrimidines as potential active site inhibitors and putative allosteric hotspots modulators of both SARS-CoV-2 MPro and PLPro
Hossein Mousavi, Behzad Zeynizadeh, Mehdi Rimaz
Bioorganic Chemistry (2023) Vol. 135, pp. 106390-106390
Open Access | Times Cited: 26
Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2in vitroandin vivo
Takayuki Kuroda, Haruaki Nobori, Keita Fukao, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 4, pp. 946-952
Open Access | Times Cited: 24
Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease
Julia M. Flynn, Qiu Yu J. Huang, Sarah N. Zvornicanin, et al.
ACS Infectious Diseases (2023) Vol. 9, Iss. 7, pp. 1372-1386
Open Access | Times Cited: 23
The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19
Miklós Bege, Anikó Borbás
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 217-217
Open Access | Times Cited: 14
Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches
Natalie Fuchs, Longfei Zhang, Laura Calvo‐Barreiro, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 1, pp. 68-68
Open Access | Times Cited: 8
Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study
Shuxia Wang, Jin Sun, Xin Zhang, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102468-102468
Open Access | Times Cited: 8
Developing BioNavi for Hybrid Retrosynthesis Planning
Tao Zeng, Zhehao Jin, Shuangjia Zheng, et al.
JACS Au (2024) Vol. 4, Iss. 7, pp. 2492-2502
Open Access | Times Cited: 8
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Wen‐Jing Xiao, Wenjie Jiang, Zheng Chen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening
Vishnu Mini Sasi, Sven Ullrich, Jennifer Ton, et al.
Biochemistry (2022) Vol. 61, Iss. 22, pp. 2495-2505
Open Access | Times Cited: 35
Natural tannins as anti-SARS-CoV-2 compounds
Shao‐Chun Wang, I-Wen Chou, Mien‐Chie Hung
International Journal of Biological Sciences (2022) Vol. 18, Iss. 12, pp. 4669-4676
Open Access | Times Cited: 33
Viral proteases as therapeutic targets
Taťána Majerová, Jan Konvalinka
Molecular Aspects of Medicine (2022) Vol. 88, pp. 101159-101159
Open Access | Times Cited: 33
Simultaneous determination of nirmatrelvir and ritonavir in human plasma using LC–MS/MS and its pharmacokinetic application in healthy Chinese volunteers
Chenxi Liu, Miqun Zhu, Liyun Cao, et al.
Biomedical Chromatography (2022) Vol. 36, Iss. 11
Closed Access | Times Cited: 32
A sustainable synthesis of the SARS-CoV-2 Mpro inhibitor nirmatrelvir, the active ingredient in Paxlovid
Joseph R. A. Kincaid, Juan C. Caravez, Karthik S. Iyer, et al.
Communications Chemistry (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top